EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Peptide Therapeutics for Solid Tumors: Functional Classes, AI‐Enhanced Discovery and Clinical Advances

Jinqiu Liang, Xiaochuan Tang, Haoqi Li, Yan Fang, Feng Jiang iD

Journal of Peptide Science · 2026-09 · 32 (9)

DOI: 10.1002/psc.70119 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Peptide Science, online erschienen am 04.08.2026. Verfasst von Jinqiu Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Neoplasms, Artificial Intelligence, Peptides, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Project Program of Nature Science Foundation of Jiangsu Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Solid tumors, the most prevalent form of malignancy, pose therapeutic challenges distinct from hematologic malignancies due to their complex biology, including high tumor heterogeneity, a dense extracellular matrix (ECM), an immunosuppressive tumor microenvironment (TME), and multifaceted drug resistance. Peptide drugs have emerged as a focal point in precision oncology, combining the deep tissue penetration of small molecules with the high target specificity, low immunogenicity, and sequence designability of antibodies. This review systematically summarizes advancements in peptide‐based therapeutics for solid tumors from 2020 to 2025. These agents are categorized by function into five classes: tumor‐homing peptides, surface receptor antagonist/inhibitory peptides, interfering peptides, peptide vaccines, and cell‐penetrating peptides as delivery tools. We also highlight the transformative role of artificial intelligence (AI) in peptide design and discovery. Finally, we discuss outcomes from clinical trials of peptide drugs in solid tumors, underscoring their potential as multifunctional agents in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsArtificial IntelligencePeptidesAntineoplastic AgentsDrug DiscoveryHumansTumor MicroenvironmentAnimals

Stichwörter der Autor:innen

artificial intelligenceimmunotherapypeptide drugspeptide‐drug conjugatessolid tumorstargeted deliverytumor‐homing peptides

Substanzen

PeptidesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, China.

ORCID-Profile: Feng Jiang

Förderung

  • Project Program of Nature Science Foundation of Jiangsu Province of China

Zitieren

APA

Liang, J., Tang, X., Li, H., Fang, Y., & Jiang, F. (2026). Peptide Therapeutics for Solid Tumors: Functional Classes, AI‐Enhanced Discovery and Clinical Advances. Journal of Peptide Science, 32(9). https://doi.org/10.1002/psc.70119

Vancouver

Liang J, Tang X, Li H, Fang Y, Jiang F. Peptide Therapeutics for Solid Tumors: Functional Classes, AI‐Enhanced Discovery and Clinical Advances. Journal of Peptide Science. 2026;32(9). doi:10.1002/psc.70119

BibTeX
@article{Liang2026,
  author = {Liang, Jinqiu and Tang, Xiaochuan and Li, Haoqi and Fang, Yan and Jiang, Feng},
  title = {Peptide Therapeutics for Solid Tumors: Functional Classes, AI‐Enhanced Discovery and Clinical Advances},
  journal = {Journal of Peptide Science},
  year = {2026},
  volume = {32},
  number = {9},
  doi = {10.1002/psc.70119}
}
Kostenlos starten →